If pharma wants patients and patient groups capable of working with it at every stage of the drug development process it must listen to, and contribute to training and funding them
In the face of massive patient need, there’s plenty pharma can do to help. The crisis is also an opportunity for it to transform the way it works with patients.
As medical affairs increasingly engages with new stakeholders - HTA bodies, regulators and patient groups - it must upskill and upgrade its data and collaboration capabilities